Eye disorders in patients with multiple sclerosis: Natural history and management

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1409-1422

  Graves, Jennifer ^a   Balcer, Laura J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diplopia; Internuclear ophthalmoparesis; Nystagmus; Optic neuritis; Vision

Indexed keywords

BACLOFEN; BETA1A INTERFERON; CLONAZEPAM; CORTICOSTEROID; GABAPENTIN; GLATIRAMER; HLA DR2 ANTIGEN; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; MECOBALAMIN; MEMANTINE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ACUTE DEMYELINATING OPTIC NEURITIS; ANEMIA; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONTRAST SENSITIVITY; CORTICOSTEROID THERAPY; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DYSPNEA; EVOKED VISUAL RESPONSE; EYE DISEASE; EYE EXAMINATION; EYE FIXATION; EYE INFLAMMATION; EYE MOVEMENT DISORDER; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; INTERMEDIATE UVEITIS; INTERNUCLEAR OPHTHALMOPARESIS; IRIDOCYCLITIS; LIVER DYSFUNCTION; LONG TERM CARE; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; LOW CONTRAST LETTER ACUITY CHART; MEDIAL LONGITUDINAL BUNDLE; MOOD DISORDER; MULTIPLE SCLEROSIS; MYALGIA; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; RECURRENCE RISK; RETINA; RETINA PERIPHLEBITIS; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; SACCADIC DYSMETRIA; SACCADIC EYE MOVEMENT; SACCADIC INTRUSION; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH IRRITATION; THICKNESS; THORAX PAIN; UVEITIS; VASODILATATION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; WHITE MATTER;

EID: 78650700677     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S6383     Document Type: Review

References (157)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:333-336.
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007;68:326-337.
3. Poser CM. Prevalence of multiple sclerosis. Ann Neurol. 1992;32: 716-717; author reply 718-719.
4. Poser CM, Brinar VV. The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology. 2007;29:150-155.
5. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419-425.
6. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101-1108.
7. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005;64:992-995.
8. Balcer LJ, Baier ML, Pelak VS, et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler. 2000;6:163-171.
9. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006;113:324-332.
10. Zaveri MS, Conger A, Salter A, et al. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol. 2008;65:924-928.
11. Talman LS, Bisker ER, Sackel DJ, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in mulitple sclerosis. Ann Neurol. 2010;67:749-760.
12. Kolappan M, Henderson AP, Jenkins TM, et al. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol. 2009;256:305-319.
13. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673-1678.
14. Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol. 1988;106:1051-1053.
15. Beck RW, Cleary PA, Anderson MM Jr, et al; The Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581-588.
16. Cleary PA, Beck RW, Anderson MM Jr, Kenny DJ, Backlund JY, Gilbert PR. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials. 1993;14:123-142.
17. Beck RW, Cleary PA. Optic Neuritis Treatment Trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773-775.
18. Beck RW. The optic Neuritis Treatment Trial: three-year follow-up results. Arch Ophthalmol. 1995;113:136-137.
19. Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol. 2004;137:77-83.
20. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002;360:1953-1962.
21. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003;121:944-949.
22. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology. 1997;49:1404-1413.
23. Hayreh SS. Anterior ischemic optic neuropathy. Clin Neurosci. 1997;4:251-263.
24. The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273:625-632.
25. Hazin R, Khan F, Bhatti MT. Neuromyelitis optica: current concepts and prospects for future management. Curr Opin Ophthalmol. 2009;20:434-439.
26. Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4:202-214.
27. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815.
28. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-1489.
29. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010;81:109-111.
30. Cabrera-Gómez JA, Bonnan M, González-Quevedo A, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsingneuromyelitis optica in Cuba and French West Indies. Mult Scler. 2009;15:828-833.
31. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009;66:1134-1138.
32. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114:810-815.
33. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. NMO predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566-569.
34. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197-2200.
35. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15:487-492.
36. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219-1220.
37. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128-1133.
38. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270-1272.
39. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443-1448.
40. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION): a newly recognised steroid responsive syndrome seemingly distinct from sarcoidosis. Brain. 2003;126:276-284.
41. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. Am J Ophthalmol. 1996;121:547-553.
42. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology. 2003;61:1367-1373.
43. Klistorner A, Fraser C, Garrick R, Graham S, Arvind H. Correlation between full-field and multifocal VEPs in optic neuritis. Doc Ophthalmol. 2008;116:19-27.
44. Frederiksen JL, Petrera J. Serial visual evoked potentials in 90 untreated patients with acute optic neuritis. Surv Ophthalmol. 1999;44 Suppl 1: S54-S62.
45. Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988;38: 175-179.
46. Hood DC, Odel JG, Winn BJ. The multifocal visual evoked potential. J Neuroophthalmol. 2003;23:279-289.
47. Fraser CL, Klistorner A, Graham SL, Garrick R, Billson FA, Grigg JR. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology. 2006;113:323 e1-e2.
48. Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109:1679-1684.
49. Hickman SJ, Miszkiel KA, Plant GT, Miller DH. The optic nerve sheath on MRI in acute optic neuritis. Neuroradiology. 2005;47:51-55.
50. Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74: 1577-1580.
51. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993;116(Pt 1):135-146.
52. Hickman SJ. Optic nerve imaging in multiple sclerosis. J Neuroimaging. 2007;17 Suppl 1:S42-S45.
53. Jackson A, Sheppard S, Laitt RD, Kassner A, Moriarty D. Optic neuritis: MR imaging with combined fat-and water-suppression techniques. Radiology. 1998;206:57-63.
54. Kallenbach K, Frederiksen J. Optical coherence tomography in optic neuritis and multiple sclerosis: a review. Eur J Neurol. 2007;14:841-849.
55. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254:1178-1181.
56. Hee MR, Izatt JA, Swanson EA, et al. Optical coherence tomography of the human retina. Arch Ophthalmol. 1995;113:325-332.
57. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59: 963-969.
58. Costello F, Hodge W, Pan YI, Eggenberger E, Coupland S, Kardon RH. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler. 2008;14: 893-905.
59. Villoslada P, Sepulcre J, Toledo J, Bejarano B. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2008;71:1747; author reply 1747-1748.
60. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69:1603-1609.
61. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58:383-391.
62. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101:1771-1778.
63. Beck RW, Cleary PA, Trobe JD, et al; The Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993; 329:1764-1769.
64. Wakakura M, Mashimo K, Oono S, et al; Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Jpn J Ophthalmol. 1999;43:133-138.
65. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435-442.
66. The Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1997;115:1545-1552.
67. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52:1479-1484.
68. Jacobs LD, Beck RW, Simon JH, et al; CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898-904.
69. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002;51:481-490.
70. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132: 463-471.
71. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66:678-684.
72. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576-1582.
73. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006; 67:1242-1249.
74. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58:840-846.
75. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50: 121-127.
76. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, doubleblind, placebo-controlled trial. Lancet. 2009;374:1503-1511.
77. Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology. 2007;69:2085-2092.
78. Siger M, Dziegielewski K, Jasek L, et al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol. 2008;255:1555-1560.
79. Frohman EM, Dwyer MG, Frohman T, et al. Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci. 2009;282:96-105.
80. Grazioli E, Zivadinov R, Weinstock-Guttman B, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008;268:12-17.
81. Keltner JL, Johnson CA, Spurr JO, Beck RW; Optic Neuritis Study Group. Baseline visual field profile of optic neuritis. The experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1993;111:231-234.
82. Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1994;112:946-953.
83. Plant GT, Kermode AG, Turano G, et al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology. 1992;42:68-76.
84. Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology. 1999;52:179-181.
85. Newman NJ. Multiple sclerosis. In: Miller NR, Newman NJ, editors. Multiple Sclerosis. Baltimore: William and Wilkins; 1998: 5539-5676.
86. Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm. 2004;12:137-142.
87. Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol. 2005;16:315-320.
88. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 2002; 16:183-200.
89. Gordon LK. Uveitis and neurological diseases. Br J Ophthalmol. 2004;88:1483-1484.
90. Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001;9:93-102.
91. Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology. 1999;106:594-599.
92. Oruc S, Duffy BF, Mohanakumar T, Kaplan HJ. The association of HLA class II with pars planitis. Am J Ophthalmol. 2001;131:657-659.
93. Malinowski SM, Pulido JS, Goeken NE, Brown CK, Folk JC. The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology. 1993;100:1199-1205.
94. Arnold AC, Pepose JS, Hepler RS, Foos RY. Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics. Ophthalmology. 1984;91:255-262.
95. Engell T. Neurological disease activity in multiple sclerosis patients with periphlebitis retinae. Acta Neurol Scand. 1986;73:168-172.
96. Tola MR, Granieri E, Casetta I, et al. Retinal periphlebitis in multiple sclerosis: a marker of disease activity? Eur Neurol. 1993;33:93-96.
97. Toussaint D. [Changes in the optic fundus in multiple sclerosis]. Bull Soc Belge Ophtalmol. 1982;199-200:235-256.
98. Adams CW, Poston RN, Buk SJ, Sidhu YS, Vipond H. Inflammatory vasculitis in multiple sclerosis. J Neurol Sci. 1985;69:269-283.
99. Engell T, Jensen OA, Klinken L. Periphlebitis retinae in multiple sclerosis. A histopathological study of two cases. Acta Ophthalmol (Copenh). 1985;63:83-88.
100. Hornsten G. The relation of retinal periphlebitis to multiple sclerosis and other neurological disorders. Acta Neurol Scand. 1971;47:413-425.
101. Downey DL, Stahl JS, Bhidayasiri R, et al. Saccadic and vestibular abnormalities in multiple sclerosis: sensitive clinical signs of brainstem and cerebellar involvement. Ann NY Acad Sci. 2002;956: 438-440.
102. Serra A, Derwenskus J, Downey DL, Leigh RJ. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J Neurol. 2003;250:569-575.
103. Frohman EM, Zhang H, Kramer PD, et al. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology. 2001;57:762-768.
104. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4: 111-121.
105. Bolanos I, Lozano D, Cantu C. Internuclear ophthalmoparesis: causes and long-term follow-up in 65 patients. Acta Neurol Scand. 2004;110:161-165.
106. Keane JR. Internuclear ophthalmoparesis: unusual causes in 114 of 410 patients. Arch Neurol. 2005;62:714-717.
107. Tsuda H, Ishikawa H, Matsunaga H, Mizutani T. [A neuroophthalmological analysis in 80 cases of multiple sclerosis]. Rinsho Shinkeigaku. 2004;44:513-521.
108. Frohman TC, Frohman EM, O'Suilleabhain P, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003;61:848-850.
109. Frohman EM, Frohman TC, O'Suilleabhain P, et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry. 2002;73:51-55.
110. Frohman EM, O'Suilleabhain P, Dewey RB Jr, Frohman TC, Kramer PD. A new measure of dysconjugacy in INO: the first-pass amplitude. J Neurol Sci. 2003;210:65-71.
111. Zee DS, Hain TC, Carl JR. Abduction nystagmus in internuclear ophthalmoparesis. Ann Neurol. 1987;21:383-388.
112. Baloh RW, Yee RD, Honrubia V. Internuclear ophthalmoparesis. I. Saccades and dissociated nystagmus. Arch Neurol. 1978;35: 484-489.
113. Zee DS. Internuclear ophthalmoparesis: pathophysiology and diagnosis. Baillieres Clin Neurol. 1992;1:455-470.
114. Bronstein AM, Rudge P, Gresty MA, Du Boulay G, Morris J. Abnormalities of horizontal gaze. Clinical, oculographic and magnetic resonance imaging findings. II. Gaze palsy and internuclear ophthalmoparesis. J Neurol Neurosurg Psychiatry. 1990; 53:200-207.
115. Kommerell G, Olivier D, Theopold H. Adaptive programming of phasic and tonic components in saccadic eye movements. Investigations of patients with abducens palsy. Invest Ophthalmol. 1976;15: 657-660.
116. Evinger LC, Fuchs AF, Baker R. Bilateral lesions of the medial longitudinal fasciculus in monkeys: effects on the horizontal and vertical components of voluntary and vestibular induced eye movements. Exp Brain Res. 1977;28:1-20.
117. Ranalli PJ, Sharpe JA. Vertical vestibulo-ocular reflex, smooth pursuit and eye-head tracking dysfunction in internuclear ophthalmoparesis. Brain. 1988;111(Pt 6):1299-1317.
118. Lewis RF, Zee DS. Ocular motor disorders associated with cerebellar lesions: pathophysiology and topical localization. Rev Neurol (Paris). 1993;149:665-677.
119. Leigh RJ, Zee DS. The Neurology of Eye Movements. 3rd ed. New York, NY: Oxford University Press; 1999.
120. Ashe J, Hain TC, Zee DS, Schatz NJ. Microsaccadic flutter. Brain. 1991;114(Pt 1B):461-472.
121. Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. J Neurol Neurosurg Psychiatry. 2003;74:1-4.
122. Serra A, Liao K, Martinez-Conde S, Optican LM, Leigh RJ. Suppression of saccadic intrusions in hereditary ataxia by memantine. Neurology. 2008;70:810-812.
123. Liu GT, Volpe NJ, Galetta SL. Neuro-Opthalmology: Diagnosis and Management. 1st ed. Philadelphia, PA: WB Saunders Company; 2001.
124. Averbuch-Heller L, Zivotofsky AZ, Das VE, DiScenna AO, Leigh RJ. Investigations of the pathogenesis of acquired pendular nystagmus. Brain. 1995;118(Pt 2):369-378.
125. Lopez LI, Bronstein AM, Gresty MA, Du Boulay EP, Rudge P. Clinical and MRI correlates in 27 patients with acquired pendular nystagmus. Brain. 1996;119(Pt 2):465-472.
126. Barton JJ, Cox TA, Digre KB. Acquired convergence-evoked pendular nystagmus in multiple sclerosis. J Neuroophthalmol. 1999;19: 34-38.
127. Barton JJ, Cox TA. Acquired pendular nystagmus in multiple sclerosis: clinical observations and the role of optic neuropathy. J Neurol Neurosurg Psychiatry. 1993;56:262-267.
128. Averbuch-Heller L. Acquired Nystagmus. Curr Treat Options Neurol. 1999;1:68-73.
129. Armstrong RA. Multiple sclerosis and the eye. Ophthalmic Physiol Opt. 1999;19 Suppl 2:S32-S42.
130. Sandramouli S, Benamer HT, Mantle M, Chavan R. See-saw nystagmus as the presenting sign in multiple sclerosis. J Neuroophthalmol. 2005; 25:56-57.
131. Matsumoto S, Ohyagi Y, Inoue I, et al. Periodic alternating nystagmus in a patient with MS. Neurology. 2001;56:276-277.
132. Strupp M, Schuler O, Krafczyk S, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61:165-170.
133. Kalla R, Glasauer S, Schautzer F, et al. 4-Aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology. 2004;62:1228-1229.
134. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818-825.
135. Jain S, Proudlock F, Constantinescu CS, Gottlob I. Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. Am J Ophthalmol. 2002;134:780-782.
136. Currie JN, Matsuo V. The use of clonazepam in the treatment of nystagmus-induced oscillopsia. Ophthalmology. 1986;93:924-932.
137. Young YH, Huang TW. Role of clonazepam in the treatment of idiopathic downbeat nystagmus. Laryngoscope. 2001;111:1490-1493.
138. Dieterich M, Straube A, Brandt T, Paulus W, Buttner U. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry. 1991;54:627-632.
139. Starck M, Albrecht H, Pollmann W, Straube A, Dieterich M. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244:9-16.
140. Starck M, Albrecht H, Pollmann W, Dieterich M, Straube A. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol. 2010;257(3):322-327.
141. Smith RM, Oommen BS, Stahl JS. Application of adaptive filters to visual testing and treatment in acquired pendular nystagmus. J Rehabil Res Dev. 2004;41:313-324.
142. Strupp M, Brandt T. Pharmacological advances in the treatment of neuro-otological and eye movement disorders. Curr Opin Neurol. 2006;19:33-40.
143. Wang Z, Dell'Osso LF, Zhang Z, Leigh RJ, Jacobs JB. Tenotomy does not affect saccadic velocities: suport for the "small-signal" gain hypothesis. Vision Res. 2006;46:2259-2267.
144. Balcer LJ. Anatomic review and topographic diagnosis. Ophthalmol Clin North Am. 2001;14:1-21, vii.
145. Sharpe JA, Goldberg HJ, Lo AW, Herishanu YO. Visual-vestibular interaction in multiple sclerosis. Neurology. 1981;31:427-433.
146. Niestroy A, Rucker JC, Leigh RJ. Neuro-ophthalmologic aspects of multiple sclerosis: using eye movements as a clinical and experimental tool. Clin Ophthalmol. 2007;1:267-272.
147. Wall M, Wray SH. The one-and-a-half syndrome - a unilateral disorder of the pontine tegmentum: a study of 20 cases and review of the literature. Neurology. 1983;33:971-980.
148. Frohman EM, Dewey RB, Frohman TC. An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms. Mult Scler. 2004;10:322-325.
149. Lee WB, Berger JR, O'Halloran HS. Parinaud syndrome heralding MS. Neurology. 2003;60:322.
150. Thomke F, Lensch E, Ringel K, Hopf HC. Isolated cranial nerve palsies in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63: 682-685.
151. Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch Ophthalmol. 1981;99:76-79.
152. Moster ML, Savino PJ, Sergott RC, Bosley TM, Schatz NJ. Isolated sixth-nerve palsies in younger adults. Arch Ophthalmol. 1984;102: 1328-1330.
153. Ksiazek SM, Repka MX, Maguire A, et al. Divisional oculomotor nerve paresis caused by intrinsic brainstem disease. Ann Neurol. 1989;26:714-718.
154. Bentley PI, Kimber T, Schapira AH. Painful third nerve palsy in MS. Neurology. 2002;58:1532.
155. Jacobson DM, Moster ML, Eggenberger ER, Galetta SL, Liu GT. Isolated trochlear nerve palsy in patients with multiple sclerosis. Neurology. 1999;53:877-879.
156. Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273-1280.
157. Burkholder BM, Galetta SL, Balcer LJ. Acute demyelinating optic neuritis. Expert Rev Ophthalmol. 2006;1:159-170.